Search - tctmd.com

Displaying 1 - 9 of 9

Sort: Relevancy | Date

For Monotherapy, P2Y12 Inhibitor Bests Aspirin After PCI for ACS: Meta-analysis

News Daily News

For Monotherapy, P2Y12 Inhibitor Bests Aspirin After PCI for ACS: Meta-analysis

Yael L. Maxwell

August 14, 2025

Trade-offs With Invasive Strategy in Older Patients With ACS: Meta-analysis

News Daily News

Trade-offs With Invasive Strategy in Older Patients With ACS: Meta-analysis

Michael O'Riordan

July 03, 2025

Fewer MACCE With P2Y12 Inhibitor vs Aspirin Monotherapy Over 5 Years

News Daily News

Fewer MACCE With P2Y12 Inhibitor vs Aspirin Monotherapy Over 5 Years

Yael L. Maxwell

June 09, 2025

Short DAPT All That’s Needed With Contemporary DES: HOST-IDEA at 3 Years

News Conference News EuroPCR 2025

Short DAPT All That’s Needed With Contemporary DES: HOST-IDEA at 3 Years

Yael L. Maxwell

June 02, 2025

Complete Revascularization in STEMI Still Superior at 10 Years: DANAMI-3-PRIMULTI

News Conference News EuroPCR 2025

Complete Revascularization in STEMI Still Superior at 10 Years: DANAMI-3-PRIMULTI

Michael O'Riordan

May 20, 2025

Early Combo Therapy With Ezetimibe Lowers MACE Risk After MI

News Daily News

Early Combo Therapy With Ezetimibe Lowers MACE Risk After MI

Michael O'Riordan

April 22, 2025

ISCHEMIA: No Clinical Event Reduction With Invasive Strategy in CTO Patients

News Daily News

ISCHEMIA: No Clinical Event Reduction With Invasive Strategy in CTO Patients

Michael O'Riordan

March 26, 2025

REVIVED/STICHES Analysis Questions Surgery’s Benefit in Ischemic HF

News Daily News

REVIVED/STICHES Analysis Questions Surgery’s Benefit in Ischemic HF

Michael O'Riordan

March 11, 2025

Benefits of Various SGLT2 Inhibitors Mostly Consistent in Observational Study

News Daily News

Benefits of Various SGLT2 Inhibitors Mostly Consistent in Observational Study

Michael O'Riordan

January 22, 2025

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.